Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
NCT ID: NCT04164199
Last Updated: 2025-12-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
PHASE3
430 participants
INTERVENTIONAL
2019-12-19
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
R - Tislelizumab and Surzebiclimab and LBL-007 Combination Therapy
Tislelizumab
Administered intravenously.
Surzebiclimab
Administered intravenously.
LBL-007
Administered intravenously.
P - Tislelizumab and Zanidatamab Combination Therapy
Tislelizumab
Administered intravenously.
Zanidatamab
Administered intravenously.
Q - Tislelizumab and LBL-007 Combination Therapy
Tislelizumab
Administered intravenously.
LBL-007
Administered intravenously.
A - Tislelizumab Monotherapy
Tislelizumab
Administered intravenously.
B - Pamiparib Monotherapy
Pamiparib
Administered orally.
C - Sitravatinib Monotherapy
Sitravatinib
Administered orally.
D - BGB-15025 Monotherapy
BGB-15025
Administered orally.
E - Zanidatamab Monotherapy
Zanidatamab
Administered intravenously.
F - Pamiparib and Temozolomide Combination Therapy
Pamiparib
Administered orally.
Temozolomide
Administered orally.
G - Tislelizumab and Pamiparib Combination Therapy
Tislelizumab
Administered intravenously.
Pamiparib
Administered orally.
H - Tislelizumab and Sitravatinib Combination Therapy
Tislelizumab
Administered intravenously.
Sitravatinib
Administered orally.
I - Tislelizumab and Ociperlimab Combination Therapy
Tislelizumab
Administered intravenously.
Ociperlimab
Administered intravenously.
J - Tislelizumab and BAT1706 Combination Therapy, or BAT1706 Monotherapy
Tislelizumab
Administered intravenously.
BAT1706
Administered intravenously.
K - Tislelizumab and Fruquintinib Combination Therapy
Tislelizumab
Administered intravenously.
Fruquintinib
Administered orally.
L - Tislelizumab and BGB-A445 Combination Therapy
Tislelizumab
Administered intravenously.
BGB-A445
Administered intravenously.
M - Tislelizumab and Surzebiclimab Combination Therapy
Tislelizumab
Administered intravenously.
Surzebiclimab
Administered intravenously.
N - Tislelizumab and BGB-15025 Combination Therapy
Tislelizumab
Administered intravenously.
BGB-15025
Administered orally.
O - Tislelizumab and Lenvatinib Combination Therapy
Tislelizumab
Administered intravenously.
Lenvatinib
Administered orally.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tislelizumab
Administered intravenously.
Pamiparib
Administered orally.
Temozolomide
Administered orally.
Sitravatinib
Administered orally.
Ociperlimab
Administered intravenously.
BAT1706
Administered intravenously.
Fruquintinib
Administered orally.
BGB-15025
Administered orally.
Zanidatamab
Administered intravenously.
BGB-A445
Administered intravenously.
Surzebiclimab
Administered intravenously.
Lenvatinib
Administered orally.
LBL-007
Administered intravenously.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Fulfills treatment criteria specified in the parent study protocol
3. In the opinion of the investigator, the participant will continue to benefit from and tolerate any of the parent study treatments.
4. The first dose of study treatment in the LTE study will be received within the treatment interruption period allowed by the parent study:
1. "Treatment interruption" (unplanned pause in study treatment) and "treatment break" (planned stop of study therapy) are not interchangeable. Restarting study treatment beyond the interruption period allowed by the parent study or after a treatment break will be determined by the investigator and the sponsor. Participants who have not restarted treatment within 1 year of starting a treatment break must discontinue treatment.
1. Currently participating in a BeiGene-sponsored eligible parent study in the survival follow-up portion
2. Parent study plans to have survival analysis
Exclusion Criteria
2. Have uncontrolled active systemic infection or recent infection requiring parenteral antimicrobial therapy prior to the start of the extension study
3. Have a life-threatening illness, medical condition, or organ system dysfunction that in the investigator's opinion, could compromise the participant's safety, interfere with the absorption or metabolism of investigational drugs, or put the study outcomes at undue risk
4. Underwent treatment with any systemic anticancer treatment (other than treatment permitted in the parent study) during the time between the last treatment in the parent study and the first dose of study treatment in the LTE study
5. Pregnant or lactating women
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
BeiGene
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Study Director
Role: STUDY_DIRECTOR
BeiGene
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida, United States
Memorial Sloan Kettering Cancer Center Mskcc
New York, New York, United States
Tennessee Oncology, Pllc Nashville
Nashville, Tennessee, United States
Baylor Research Institute
Dallas, Texas, United States
Prince of Wales Hospital
Randwick, New South Wales, Australia
Northern Cancer Institute
St Leonards, New South Wales, Australia
Calvary Mater Newcastle
Waratah, New South Wales, Australia
Icon Cancer Centre South Brisbane
South Brisbane, Queensland, Australia
The Queen Elizabeth Hospital
Woodville South, South Australia, Australia
Monash Health
Clayton, Victoria, Australia
Peter Maccallum Cancer Centre
Melbourne, Victoria, Australia
The Second Hospital of Anhui Medical University
Hefei, Anhui, China
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Peking University First Hospital
Beijing, Beijing Municipality, China
The Affiliated Hospital of Military Medical Sciences
Beijing, Beijing Municipality, China
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Chongqing Cancer Hospital
Chongqing, Chongqing Municipality, China
Fujian Medical University Union Hospital
Fuzhou, Fujian, China
Fujian Cancer Hospital
Fuzhou, Fujian, China
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China
Sun Yat Sen Memorial Hospital, Sun Yat Sen University (North)
Guangzhou, Guangdong, China
Affiliated Cancer Hospital and Institute of Guangzhou Medical University
Guangzhou, Guangdong, China
Guangdong Provincial Peoples Hospital
Guangzhou, Guangdong, China
Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South)
Guangzhou, Guangdong, China
Nanfang Hospital of Southern Medical University
Guangzhou, Guangdong, China
The Fifth Affiliated Hospital Sun Yat Sen University
Zhuhai, Guangdong, China
The Peoples Hospital of Guangxi Zhuang Autonomous Region
Nanning, Guangxi, China
The Second Affiliated Hospital of Zunyi Medical University
Zuiyi, Guizhou, China
Hainan Cancer Hospital
Haikou, Hainan, China
Affiliated Hospital of Hebei University
Baoding, Hebei, China
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
Henan Cancer Hospital
Zhengzhou, Henan, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, China
Zhongnan Hospital of Wuhan University Wuhan
Wuhan, Hubei, China
Hubei Cancer Hospital
Wuhan, Hubei, China
Hunan Cancer Hospital
Changsha, Hunan, China
The First Peoples Hospital of Changzhou
Changzhou, Jiangsu, China
Jiangsu Province Hospital
Nanjing, Jiangsu, China
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China
The First Affiliated Hospital of Nanchang University Branch Donghu
Nanchang, Jiangxi, China
Jilin Cancer Hospital
Changchun, Jilin, China
The First Hospital of Jilin University
Changchun, Jilin, China
First Affiliated Hospital of Dalian Medical University
Dalian, Liaoning, China
Liaoning Cancer Hospital and Institute
Shenyang, Liaoning, China
The First Affiliated Hospital of Xian Jiaotong University
Xi'an, Shaanxi, China
Shandong Cancer Hospital
Jinan, Shandong, China
Weifang Peoples Hospital
Weifang, Shandong, China
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China
Affiliated Zhongshan Hospital of Fudan University
Shanghai, Shanghai Municipality, China
Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China
West China Hospital, Sichuan University
Chengdu, Sichuan, China
West China Second University Hospital, Sichuan University
Chengdu, Sichuan, China
Institute of Hematology and Hospital of Blood Disease
Tianjin, Tianjin Municipality, China
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China
Affiliated Cancer Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, China
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
The First Provincial Wenzhou Hospital of Zhejiang
Wenzhou, Zhejiang, China
Hopital Beaujon
Clichy, , France
Hopital Prive Jean Mermoz
Lyon, , France
Icm Val Daurelle
Montpellier, , France
Centre Hospitalier Universitaire Nantes Hotel Dieu
Nantes, , France
Hopital Larchet Chu Nice
Nice, , France
Policlinico Sorsola Malpighi, Aou Di Bologna
Bologna, , Italy
Aou Pisana, Stabilimento Di Santa Chiara
Pisa, , Italy
Azienda Ospedaliera S Maria Di Terni
Terni, , Italy
Akita University Hospital
Akitashi, Akita, Japan
Chiba Cancer Center
Chiba, Chiba, Japan
Nho Kyushu Cancer Center
Fukuoka, Fukuoka, Japan
Hokkaido University Hospital
Sapporo, Hokkaido, Japan
Izumi City General Hospital
Izumishi, Osaka, Japan
The University of Osaka Hospital
Suitashi, Osaka, Japan
National Cancer Center Hospital
ChuoKu, Tokyo, Japan
University Malaya Medical Centre
Kuala Lumpur, , Malaysia
Sarawak General Hospital
Kuching, , Malaysia
Auckland City Hospital
Auckland, , New Zealand
Szpitale Pomorskie Spolka Z Ograniczona Odpowiedzialnoscia
Gdynia, , Poland
Centrum Onkologii Instytut Im M Sklodowskiej Curie
Warsaw, , Poland
Cha Bundang Medical Center, Cha University
BundangGu SeongnamSi, Gyeonggi-do, South Korea
Seoul National University Bundang Hospital
BundangGu SeongnamSi, Gyeonggi-do, South Korea
National Cancer Center (Korea)
IlsandongGu GoyangSi, Gyeonggi-do, South Korea
The Catholic University of Korea, St Vincents Hospital
PaldalGu SuwonSi, Gyeonggi-do, South Korea
Gachon University Gil Medical Center
NamdongGu, Incheon Gwang'yeogsi, South Korea
Chonnam National University Hwasun Hospital
HwasunGun, Jeollanam-do, South Korea
Smg Snu Boramae Medical Center
DongjakGu, Seoul Teugbyeolsi, South Korea
Samsung Medical Center
GangnamGu, Seoul Teugbyeolsi, South Korea
Korea University Guro Hospital
GuroGu, Seoul Teugbyeolsi, South Korea
The Catholic University of Korea, Seoul St Marys Hospital
SeochoGu, Seoul Teugbyeolsi, South Korea
Severance Hospital Yonsei University Health System
SeodaemunGu, Seoul Teugbyeolsi, South Korea
Seoul National University Hospital
Seoul, Seoul Teugbyeolsi, South Korea
Asan Medical Center
SongpaGu, Seoul Teugbyeolsi, South Korea
Ajou University Hospital
Suwon, , South Korea
Chiayi Chang Gung Memorial Hospital
Chiayi City, , Taiwan
Linkou Chang Gung Memorial Hospital
Guishan Dist, , Taiwan
Kaohsiung Chang Gung Memorial Hospital
Niaosong Dist, , Taiwan
China Medical University Hospital
North Dist, , Taiwan
National Cheng Kung University Hospital
North Dist, , Taiwan
Taichung Veterans General Hospital
Taichung, , Taiwan
Chi Mei Medical Center
Yongkang Dist, , Taiwan
King Chulalongkorn Memorial Hospital (Chulalongkorn University)
Pathum Wan, , Thailand
Acibadem Adana Hospital
Kuruköprü, , Turkey (Türkiye)
Bakirkoy Sadi Konuk Eah
stanbulBakrkoy, , Turkey (Türkiye)
Namik Kemal University
Tekirdağ, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2019-002554-23
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
BGB-A317-290-LTE1
Identifier Type: -
Identifier Source: org_study_id